Personal history of malignant neoplasm of prostate. Z85.46 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM Z85.46 became effective on October 1, 2020.
The ICD-10-CM is a catalog of diagnosis codes used by medical professionals for medical coding and reporting in health care settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates.
Why ICD-10 codes are important
Malignant neoplasm of prostate
A staging system is a standard way for the cancer care team to describe how far a cancer has spread. The most widely used staging system for prostate cancer is the AJCC TNM system, which was most recently updated in 2018.
Prostate cancer, also known as carcinoma of the prostate, is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing however, some grow relatively quickly. The cancer cells may spread from the prostate to other parts of the body, particularly the bones and lymph nodes.
The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized “head to toe” into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C61:
The overall prognosis of a patient with Malignant Neoplasm of the Prostate depends on the age, overall health of the patient, and stage of the disease process. In majority of the cases where the disease is diagnosed early the prognosis is extremely good.
The Medicare Code Editor detects and reports errors in the coding of claims data. The following ICD-9 Code Edits are applicable to this code:
As is the case with almost all types of cancers, the exact etiology of Malignant Neoplasm of the Prostate is not known but there are various risk factors that have been mentioned above which predispose an individual to developing Malignant Neoplasm of the Prostate. Genetics also play a role in the development of Malignant Neoplasm of the Prostate.
As Malignant Neoplasm of the Prostate are a very slow growing tumors, a diagnosis is not made until the patient is in his 70s. In such conditions, the treatment option is to just observe through frequent blood work checking for levels of PSA.